Which over‑the‑counter nonsteroidal anti‑inflammatory drug is more appropriate for rheumatoid arthritis: naproxen (Aleve) or ibuprofen?

Ibuprofen is the better choice for rheumatoid arthritis when selecting an over-the-counter NSAID.

Ibuprofen should be your first-line NSAID for RA, starting at 1200 mg daily (400 mg three times daily), with the option to increase to 2400 mg daily if needed. This recommendation is based on ibuprofen having the lowest gastrointestinal risk profile among NSAIDs while maintaining comparable efficacy to naproxen (Aleve) for inflammatory arthritis 1.

Safety Profile: The Critical Differentiator

The evidence consistently demonstrates that ibuprofen is the lowest-risk NSAID for serious gastrointestinal complications 1. Multiple controlled epidemiological studies reviewed by Henry et al. established that ibuprofen carries significantly less GI risk than naproxen, which is classified as "intermediate risk" alongside diclofenac 1. This safety advantage is particularly important in RA patients who require chronic NSAID therapy and often use these medications long-term.

Important Caveat on Dosing

However, there's a critical dose-dependent consideration: high-dose ibuprofen (2400 mg daily) may lose its safety advantage and become comparable in GI risk to intermediate-risk NSAIDs like naproxen 1. Therefore:

• Start with 1200 mg daily (400 mg TID) 1, 2
• Only escalate to 2400 mg daily if symptom control is inadequate 1, 2
• At maximum doses, the safety distinction between ibuprofen and naproxen diminishes

Efficacy: Essentially Equivalent

Multiple head-to-head trials demonstrate that ibuprofen and naproxen have comparable efficacy for RA 3, 4, 5. Clinical studies in RA patients show:

• Both drugs effectively control pain and inflammation 2
• No statistically significant differences in efficacy measurements between the two 3, 4
• Patient and physician preferences varied, with some studies favoring naproxen slightly, but differences were not clinically meaningful 3

The FDA label confirms ibuprofen's efficacy in RA, noting it is "comparable to aspirin in controlling pain and inflammation" and "comparable to indomethacin in controlling the signs and symptoms of disease activity" 2.

Cardiovascular and Renal Considerations

Recent large-scale evidence from the PRECISION trial provides important safety data 6:

• In RA patients specifically, celecoxib, ibuprofen, and naproxen showed similar cardiovascular event rates
• Ibuprofen demonstrated significantly lower renal event risk compared to other NSAIDs in osteoarthritis patients (HR 0.58), though RA-specific renal data were less definitive 6
• All NSAIDs carry cardiovascular risks that increase with duration of use 7

Critical Drug Interaction

If your patient takes low-dose aspirin for cardioprotection, ibuprofen can interfere with aspirin's antiplatelet effect 7, 2. To avoid this interaction:

• Take ibuprofen at least 30 minutes AFTER immediate-release aspirin, OR
• Take ibuprofen at least 8 hours BEFORE aspirin 7
• This interaction does NOT occur with naproxen, making naproxen preferable in aspirin users

Practical Treatment Algorithm

1. First choice: Ibuprofen 400 mg TID (1200 mg/day) 1, 2

   • Lowest GI risk at this dose
   • Proven efficacy in RA
   • Available OTC

2. If inadequate response after 2-4 weeks:

   • Increase to ibuprofen 600-800 mg TID (up to 2400 mg/day) 2
   • Be aware that GI safety advantage diminishes at maximum doses

3. Switch to naproxen if:

   • Patient requires concurrent aspirin therapy (to avoid drug interaction)
   • Ibuprofen fails at maximum doses
   • Patient prefers twice-daily dosing (naproxen 375-500 mg BID vs ibuprofen TID-QID)

4. Consider gastroprotection with PPI in all RA patients on chronic NSAIDs, especially those with:

   • Prior GI bleeding
   • Age >65
   • Concurrent corticosteroid use (common in RA) 1

Common Pitfalls to Avoid

• Don't assume all NSAIDs are equivalent in safety—ibuprofen's GI advantage is evidence-based and clinically meaningful 1
• Don't ignore the dose-dependent loss of safety—2400 mg ibuprofen daily approaches naproxen's risk profile 1
• Don't combine ibuprofen with aspirin without proper timing—this negates aspirin's cardioprotective effects 7
• Don't forget that OTC NSAIDs are symptomatic treatment only—RA patients require disease-modifying therapy (DMARDs) as the mainstay of treatment 8, 9

Bottom Line

Start with ibuprofen 1200 mg daily for superior GI safety while maintaining equivalent efficacy to naproxen. Reserve naproxen for patients who need aspirin co-therapy or who fail ibuprofen. Both drugs require monitoring for GI, cardiovascular, and renal adverse effects, with consideration of gastroprotection in all RA patients on chronic NSAID therapy.